Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
News|Articles|November 2, 2022
Merck and Veeva Ink 10-Year Partnership Agreement
Author(s)Pharmaceutical Technology Editors
Under this deal, Merck, known as MSD outside of the United States and Canada, will select Veeva products for industry-specific software and data.
Advertisement
Merck, known as MSD outside of the United States, and Veeva Systems, a provider of cloud systems for the life sciences industry, announced a ten-year strategic partnership agreement on Nov. 1, 2022. Under the agreement, which builds on an existing 12-year partnership between the two companies, Merck will take a “Veeva-first approach” to new industry-specific software and data. Veeva will provide Merck with a strategic pricing approach and allow Merck input into their product roadmap.
“I am excited to see our partnership with Merck evolve to this strategic level,” said Peter Gassner, CEO, Veeva, in a company press release. “Our teams share a common passion for the industry and an understanding of strategic partnership. I look forward to seeing what we create together over the coming years.”
“Transforming our digital, data, and analytics capabilities is integral to enabling our global colleagues to deliver on our purpose of using the power of leading-edge science to save and improve lives around the world,” said Robert M. Davis, CEO and president, Merck, in the release. “Our strategic partnership with Veeva expands our capacity to leverage innovative technology and enhances our ability to deliver value to patients and all our stakeholders—this is key to how we measure success.”
Source:
Advertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Advertisement
Advertisement